Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 to Distribute AdnaGen's Assays in UK, Ireland

NEW YORK (GenomeWeb News) – Lab21 will serve as exclusive distributor of AdnaGen's circulating tumor cell diagnostic assays in the UK and Ireland under an alliance announced today.

AdnaGen's AdnaTest products detect and analyze circulating tumor cells from metastatic breast cancer and metastatic colon cancer. According to the firms, AdnaGen's tests enable detection of a broad range of tumor molecular markers.

Cambridge, UK-based Lab21 said that it expects to launch the tests as a service beginning in October.

"Detecting circulating tumor cells provides physicians a means to monitor therapy," Berwyn Clarke, Chief Scientific Officer of Lab21, said in a statement. "Since cancer is evolving from a fatal condition towards a chronic disorder, Lab21 wants to position itself to offer tools for improved patient management as well as cost control. We also see this as a key new service to offer our pharmaceutical partners as they develop new anti-cancer agents."

Financial and other terms of the alliance were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.